Breakthrough Research Pipeline
The programs in our pipeline stem from our deep understanding of NK cells and unique screening approaches that exploit their innate anti-tumor biology.
"Parked" CAR-NK cells
Target Validation
NK cell Evasion and
Suppression
Target Discovery
Innate tumour recognition
Target Validation
NK cell migration
Target Discovery
Target Discovery
Target Validation
Pre-Clinical
"Parked" CAR-NK cells

Next-Generation Primary Allogeneic CAR NK cells

oNKCAR138 & oNKCAR21: CARs inserted into specific loci within primary human NK cells to regulate expression and increase NK cell activation and function.

 

NK cell Evasion and
Suppression

Biologics

Blocking antibodies and decoy receptors that prevent NK cell suppression in the tumor microenvironment, oNK05 at target validation stage.

Innate tumour recognition

Biologics

Functional genomic screens to define molecular ‘handles’ to increase NK cell targeting of tumors via Bi/Tri-specific killer engagers. oNK03 & oNK04 progressed to Target Validation

NK cell migration

Small Molecules/biologics

Targets that increase NK cell trafficking and retention within tumors.